Johnson & Johnson (JNJ) SEC Filings
Filing links are provided when reliable SEC filing data is available.
Recent Filings
| Form | Filing Date | Accepted | Document |
|---|---|---|---|
| SD | May 27, 2026 | May 27, 2026 | View filing |
| 13F-HR | May 13, 2026 | May 13, 2026 | View filing |
| 4 | May 4, 2026 | May 4, 2026 | View filing |
| SC 13G | May 1, 2026 | May 1, 2026 | View filing |
| 8-K | Apr 28, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 4 | Apr 27, 2026 | Apr 27, 2026 | View filing |
| 10-Q | Apr 22, 2026 | Apr 22, 2026 | View filing |
| 8-K | Apr 14, 2026 | Apr 14, 2026 | View filing |
| SC 13G/A | Apr 13, 2026 | Apr 13, 2026 | View filing |
| SC 13G/A | Mar 26, 2026 | Mar 26, 2026 | View filing |
| 13F-HR/A | Mar 18, 2026 | Mar 18, 2026 | View filing |
| 13F-HR/A | Mar 18, 2026 | Mar 18, 2026 | View filing |
| 4 | Mar 12, 2026 | Mar 12, 2026 | View filing |
| 4 | Mar 12, 2026 | Mar 12, 2026 | View filing |
| 4 | Mar 12, 2026 | Mar 12, 2026 | View filing |
| ARS | Mar 11, 2026 | Mar 11, 2026 | View filing |
| DEFA14A | Mar 11, 2026 | Mar 11, 2026 | View filing |
| DEF 14A | Mar 11, 2026 | Mar 11, 2026 | View filing |
| 4 | Mar 3, 2026 | Mar 3, 2026 | View filing |
| 4 | Feb 23, 2026 | Feb 23, 2026 | View filing |
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato